Highest-materiality recent filing
Bio-Techne Q4 revenue $321M, adjusted EPS $0.52; dividend $0.08; Merck deal on track
Q4 revenue $321.2M (+1% reported, +3% organic); FY26 flat at $1.2B
Bio-Techne to be acquired by Merck KGaA for $73.00 per share in all-cash deal
Merck KGaA to acquire Bio-Techne (TECH) for $73.00 per share in cash.
Merck KGaA to acquire Bio-Techne for $73/share in $11.3B deal
Purchase price $73/share in cash; enterprise value $11.3B (EUR 9.9B); 36% premium to 1-month VWAP.
Bio-Techne Q3 revenue down 2% to $311.4M, adj EPS $0.53; declares $0.08 dividend
Revenue $311.4M, down 2% reported and organic; GAAP EPS $0.32 (up from $0.14), adjusted EPS $0.53 (down from $0.56).
Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42
GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.
Bio-Techne Q1 FY2026 revenue down 1% to $286.6M; adjusted EPS flat $0.42; declares $0.08 dividend
Revenue $286.6M (-1% YoY); GAAP EPS $0.24 (up from $0.21); adjusted EPS $0.42 (flat).
GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.
Q3 organic revenue +6% to $316.2M; GAAP EPS $0.14 vs $0.31 YoY; adjusted EPS $0.56 vs $0.48 YoY.
Bio-Techne ordered to pay former CEO $35.98M over option expiration error
Arbitrator awarded former CEO Charles Kummeth $35.978M for options lost due to administrative error.
Bio-Techne Q2 organic revenue +9% to $297M, adjusted EPS $0.42; declares $0.08 dividend
Q2 organic revenue up 9% to $297.0M; GAAP EPS $0.22 vs $0.17, adjusted EPS $0.42 vs $0.40.
Bio-Techne Q1 revenue $289.5M (organic +4%), adj EPS $0.42; declares $0.08 dividend
Q1 revenue $289.5M, up 5% reported (4% organic); GAAP EPS $0.21 vs $0.31; adjusted EPS $0.42 vs $0.41.
Bio-Techne Q4 adjusted EPS $0.49 vs $0.55 YoY; revenue $306.1M (+2%)
Q4 organic revenue up 1% to $306.1M; FY2024 organic revenue up 1% to $1.2B.
Q3 revenue $303.4M (organic +2%, reported +3%); GAAP EPS $0.31 vs $0.43; adjusted EPS $0.48 vs $0.53.
Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.
Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024
Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.
Bio-Techne Q1 GAAP EPS $0.31 (down 44% YoY); CEO Kelderman appointed
GAAP diluted EPS $0.31 vs $0.55 prior year; adjusted EPS $0.41 vs $0.45.
Bio-Techne CEO Chuck Kummeth to retire; Kim Kelderman named successor effective Feb 1, 2024
Kelderman becomes COO Nov 1, 2023, then CEO and board member Feb 1, 2024; Kummeth to serve as Senior Advisor until July 1, 2024.
Bio-Techne Q4 revenue up 5% to $301.3M; GAAP EPS $0.47 vs $0.38, adjusted EPS $0.55 vs $0.51
Full-year organic revenue grew 5% to $1.1B; GAAP EPS $1.76, adjusted EPS $1.99.
Bio-Techne completes $257M investment for 20% stake in Wilson Wolf; future buyout potential $1B
$257M investment gives Bio-Techne 20% ownership of Wilson Wolf Manufacturing.
Bio-Techne invests $257M for 20% of Wilson Wolf; future buyout up to $1B
Wilson Wolf met trailing 12-month EBITDA target of $55M, triggering Bio-Techne's option.
Bio-Techne Q2 FY2023: organic revenue up 4% to $271.6M; GAAP EPS $0.31 vs $0.49 YoY
Organic revenue grew 4% to $271.6M; reported revenue up 1%.
Bio-Techne Q1 FY2023 revenue up 7% organic, GAAP EPS $2.21, declares 4-for-1 stock split
Total revenue $269.7M, up 5% reported / 7% organic YoY.
Bio-Techne Q3 FY2022 revenue $290.4M (+17% organic), record adj. EPS $2.14
Q3 organic revenue +17% to $290.4M (reported +19%); YTD organic +18% to $817.4M.
Bio-Techne Q2 FY2022: GAAP EPS $1.94, adj EPS $1.88; rev $269.3M; $0.32 dividend, $400M buyback
Organic revenue +17% to $269.3M; Protein Sciences organic growth 19% with ProteinSimple up 27% and GMP Proteins >180%.
Bio-Techne appoints Will Geist President, Protein Sciences Segment, succeeding retiring Dave Eansor
Geist, former COO of Quanterix and former VP/GM at Thermo Fisher, appointed effective Jan 3, 2022.
Bio-Techne Q1 FY2022 revenue $257.7M, organic growth 21%; adjusted EPS $1.83 vs $1.43
Q1 FY2022 revenue $257.7M, organic growth 21% (reported 26%).
Bio-Techne Q4 FY2021 revenue up 47% to $259M; adjusted EPS $1.87 vs $1.00 YoY
Q4 organic revenue rose 39% to $259.0M; GAAP EPS $0.37, adjusted EPS $1.87 (vs $1.00 prior year).
On January 30, 2025, Bio-Techne Corporation (the “Company”) appointed Dr. Amy Herr to the Company’s Board of Directors as an independent director.
On April 24, 2024, Bio-Techne Corporation (the “Company”) temporarily expanded the size of the Board of Directors from ten to eleven members and appointed Dr. Judith Klimovsky to the company's Board of Directors as an independent director.
On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.
Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
Effective November 1, 2023, Kim Kelderman will be appointed as Chief Operating Officer of the Company.
Mr. Kummeth will also retire from the Board of Directors on such date.
Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.
Effective February 1, 2024, Mr. Kummeth will transition from Chief Executive Officer to Senior Advisor until the date of his retirement on July 1, 2024.
Mr. Bohnen succeeds Brenda Furlow, who has announced her intention to retire on March 3, 2023.
appointed Mr. Shane Bohnen, age 48, as an executive officer of the Company in the position of Senior Vice President, General Counsel and Corporate Secretary, effective March 3, 2023.
On August 4, 2022, Bio-Techne Corporation (the “Company”) announced Chuck Kummeth’s plan to retire from his position as Chief Executive Officer effective June 30, 2024
Max materiality 1.00 · Median 0.65 · Most common event earnings